-
1
-
-
0026539069
-
Tuberculosis: A global overview of the situation today
-
Sudre, P., G. ten Dam, and A. Kochi. 1992. Tuberculosis: a global overview of the situation today. Bull. World Health Organ. 70: 149-159.
-
(1992)
Bull. World Health Organ.
, vol.70
, pp. 149-159
-
-
Sudre, P.1
Ten Dam, G.2
Kochi, A.3
-
2
-
-
84935892144
-
-
WHO. World Health Organization, Geneva
-
WHO. 2012. Global Tuberculosis Report 2012. World Health Organization, Geneva.
-
(2012)
Global Tuberculosis Report 2012
-
-
-
3
-
-
22944433876
-
The success and failure of BCG: Implications for a novel tuberculosis vaccine
-
Andersen, P., and T. M. Doherty. 2005. The success and failure of BCG: implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3: 656-662.
-
(2005)
Nat. Rev. Microbiol.
, vol.3
, pp. 656-662
-
-
Andersen, P.1
Doherty, T.M.2
-
4
-
-
71849091759
-
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
-
Bertholet, S., G. C. Ireton, M. Kahn, J. Guderian, R. Mohamath, N. Stride, E. M. Laughlin, S. L. Baldwin, T. S. Vedvick, R. N. Coler, and S. G. Reed. 2008. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181: 7948-7957.
-
(2008)
J. Immunol.
, vol.181
, pp. 7948-7957
-
-
Bertholet, S.1
Ireton, G.C.2
Kahn, M.3
Guderian, J.4
Mohamath, R.5
Stride, N.6
Laughlin, E.M.7
Baldwin, S.L.8
Vedvick, T.S.9
Coler, R.N.10
Reed, S.G.11
-
5
-
-
77958047728
-
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrugresistant Mycobacterium tuberculosis
-
Bertholet, S., G. C. Ireton, D. J. Ordway, H. P. Windish, S. O. Pine, M. Kahn, T. Phan, I. M. Orme, T. S. Vedvick, S. L. Baldwin, et al. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrugresistant Mycobacterium tuberculosis. Sci. Transl. Med. 2: 53ra74.
-
(2010)
Sci. Transl. Med.
, vol.2
-
-
Bertholet, S.1
Ireton, G.C.2
Ordway, D.J.3
Windish, H.P.4
Pine, S.O.5
Kahn, M.6
Phan, T.7
Orme, I.M.8
Vedvick, T.S.9
Baldwin, S.L.10
-
6
-
-
79551551963
-
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
-
Coler, R. N., S. Bertholet, M. Moutaftsi, J. A. Guderian, H. P. Windish, S. L. Baldwin, E. M. Laughlin, M. S. Duthie, C. B. Fox, D. Carter, et al. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6: e16333.
-
(2011)
PLoS One
, vol.6
-
-
Coler, R.N.1
Bertholet, S.2
Moutaftsi, M.3
Guderian, J.A.4
Windish, H.P.5
Baldwin, S.L.6
Laughlin, E.M.7
Duthie, M.S.8
Fox, C.B.9
Carter, D.10
-
7
-
-
84857482098
-
The importance of adjuvant formulation in the development of a tuberculosis vaccine
-
Baldwin, S. L., S. Bertholet, V. A. Reese, L. K. Ching, S. G. Reed, and R. N. Coler. 2012. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 188: 2189-2197.
-
(2012)
J. Immunol.
, vol.188
, pp. 2189-2197
-
-
Baldwin, S.L.1
Bertholet, S.2
Reese, V.A.3
Ching, L.K.4
Reed, S.G.5
Coler, R.N.6
-
8
-
-
66349122656
-
A critical role for CD8 T cells in a nonhuman primate model of tuberculosis
-
Chen, C. Y., D. Huang, R. C. Wang, L. Shen, G. Zeng, S. Yao, Y. Shen, L. Halliday, J. Fortman, M. McAllister, et al. 2009. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 5: e1000392.
-
(2009)
PLoS Pathog.
, vol.5
-
-
Chen, C.Y.1
Huang, D.2
Wang, R.C.3
Shen, L.4
Zeng, G.5
Yao, S.6
Shen, Y.7
Halliday, L.8
Fortman, J.9
McAllister, M.10
-
9
-
-
84871839521
-
IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection
-
Green, A. M., R. Difazio, and J. L. Flynn. 2013. IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J. Immunol. 190: 270-277.
-
(2013)
J. Immunol.
, vol.190
, pp. 270-277
-
-
Green, A.M.1
Difazio, R.2
Flynn, J.L.3
-
10
-
-
0037011066
-
HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells
-
Heinzel, A. S., J. E. Grotzke, R. A. Lines, D. A. Lewinsohn, A. L. McNabb, D. N. Streblow, V. M. Braud, H. J. Grieser, J. T. Belisle, and D. M. Lewinsohn. 2002. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J. Exp. Med. 196: 1473-1481.
-
(2002)
J. Exp. Med.
, vol.196
, pp. 1473-1481
-
-
Heinzel, A.S.1
Grotzke, J.E.2
Lines, R.A.3
Lewinsohn, D.A.4
McNabb, A.L.5
Streblow, D.N.6
Braud, V.M.7
Grieser, H.J.8
Belisle, J.T.9
Lewinsohn, D.M.10
-
11
-
-
0037106372
-
Human dendritic cells presenting adenovirally expressed antigen elicit Mycobacterium tuberculosis-specific CD8+ T cells
-
Lewinsohn, D. A., R. A. Lines, and D. M. Lewinsohn. 2002. Human dendritic cells presenting adenovirally expressed antigen elicit Mycobacterium tuberculosis-specific CD8+ T cells. Am. J. Respir. Crit. Care Med. 166: 843-848.
-
(2002)
Am. J. Respir. Crit. Care Med.
, vol.166
, pp. 843-848
-
-
Lewinsohn, D.A.1
Lines, R.A.2
Lewinsohn, D.M.3
-
12
-
-
84874684544
-
+ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates
-
+ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates. Mol. Med. 18: 647-658.
-
(2012)
Mol. Med.
, vol.18
, pp. 647-658
-
-
Rahman, S.1
Magalhaes, I.2
Rahman, J.3
Ahmed, R.K.4
Sizemore, D.R.5
Scanga, C.A.6
Weichold, F.7
Verreck, F.8
Kondova, I.9
Sadoff, J.10
-
13
-
-
0035125898
-
CD8- and CD95/95Ldependent mechanisms of resistance in mice with chronic pulmonary tuberculosis
-
Turner, J., C. D. D'Souza, J. E. Pearl, P. Marietta, M. Noel, A. A. Frank, R. Appelberg, I. M. Orme, and A. M. Cooper. 2001. CD8- and CD95/95Ldependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am. J. Respir. Cell Mol. Biol. 24: 203-209.
-
(2001)
Am. J. Respir. Cell Mol. Biol.
, vol.24
, pp. 203-209
-
-
Turner, J.1
D'Souza, C.D.2
Pearl, J.E.3
Marietta, P.4
Noel, M.5
Frank, A.A.6
Appelberg, R.7
Orme, I.M.8
Cooper, A.M.9
-
14
-
-
0034529550
-
Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells
-
van Pinxteren, L. A., J. P. Cassidy, B. H. Smedegaard, E. M. Agger, and P. Andersen. 2000. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30: 3689-3698.
-
(2000)
Eur. J. Immunol.
, vol.30
, pp. 3689-3698
-
-
Van Pinxteren, L.A.1
Cassidy, J.P.2
Smedegaard, B.H.3
Agger, E.M.4
Andersen, P.5
-
15
-
-
33845595414
-
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis
-
Bennekov, T., J. Dietrich, I. Rosenkrands, A. Stryhn, T. M. Doherty, and P. Andersen. 2006. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur. J. Immunol. 36: 3346-3355.
-
(2006)
Eur. J. Immunol.
, vol.36
, pp. 3346-3355
-
-
Bennekov, T.1
Dietrich, J.2
Rosenkrands, I.3
Stryhn, A.4
Doherty, T.M.5
Andersen, P.6
-
16
-
-
65249121913
-
CD4 and CD8 T cell responses to the M tuberculosis Ag85B-TB104 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination
-
Elvang, T., J. P. Christensen, R. Billeskov, T. Thi Kim Thanh Hoang, P. Holst, A. R. Thomsen, P. Andersen, and J. Dietrich. 2009. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One 4: e5139.
-
(2009)
PLoS One
, vol.4
-
-
Elvang, T.1
Christensen, J.P.2
Billeskov, R.3
Hoang, T.T.K.T.4
Holst, P.5
Thomsen, A.R.6
Andersen, P.7
Dietrich, J.8
-
17
-
-
56849108004
-
RBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector
-
Magalhaes, I., D. R. Sizemore, R. K. Ahmed, S. Mueller, L. Wehlin, C. Scanga, F. Weichold, G. Schirru, M. G. Pau, J. Goudsmit, et al. 2008. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 3: e3790.
-
(2008)
PLoS One
, vol.3
-
-
Magalhaes, I.1
Sizemore, D.R.2
Ahmed, R.K.3
Mueller, S.4
Wehlin, L.5
Scanga, C.6
Weichold, F.7
Schirru, G.8
Pau, M.G.9
Goudsmit, J.10
-
18
-
-
80054004840
-
Tuberculosis vaccine promises sterilizing immunity
-
McShane, H., and A. Williams. 2011. Tuberculosis vaccine promises sterilizing immunity. Nat. Med. 17: 1185-1186.
-
(2011)
Nat. Med.
, vol.17
, pp. 1185-1186
-
-
McShane, H.1
Williams, A.2
-
19
-
-
84864758568
-
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
-
Odutola, A. A., O. A. Owolabi, P. K. Owiafe, H. McShane, and M. O. Ota. 2012. A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. Vaccine 30: 5591-5594.
-
(2012)
Vaccine
, vol.30
, pp. 5591-5594
-
-
Odutola, A.A.1
Owolabi, O.A.2
Owiafe, P.K.3
McShane, H.4
Ota, M.O.5
-
20
-
-
84864752976
-
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
-
Pathan, A. A., A. M. Minassian, C. R. Sander, R. Rowland, D. W. Porter, I. D. Poulton, A. V. Hill, H. A. Fletcher, and H. McShane. 2012. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 30: 5616-5624.
-
(2012)
Vaccine
, vol.30
, pp. 5616-5624
-
-
Pathan, A.A.1
Minassian, A.M.2
Sander, C.R.3
Rowland, R.4
Porter, D.W.5
Poulton, I.D.6
Hill, A.V.7
Fletcher, H.A.8
McShane, H.9
-
21
-
-
77949532239
-
Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection
-
Ronan, E. O., L. N. Lee, P. C. Beverley, and E. Z. Tchilian. 2009. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS One 4: e8235.
-
(2009)
PLoS One
, vol.4
-
-
Ronan, E.O.1
Lee, L.N.2
Beverley, P.C.3
Tchilian, E.Z.4
-
22
-
-
79957584452
-
Tuberculosis vaccines in clinical trials
-
Rowland, R., and H. McShane. 2011. Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines 10: 645-658.
-
(2011)
Expert Rev. Vaccines
, vol.10
, pp. 645-658
-
-
Rowland, R.1
McShane, H.2
-
23
-
-
33746632535
-
Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis
-
Santosuosso, M., S. McCormick, X. Zhang, A. Zganiacz, and Z. Xing. 2006. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74: 4634-4643.
-
(2006)
Infect. Immun.
, vol.74
, pp. 4634-4643
-
-
Santosuosso, M.1
McCormick, S.2
Zhang, X.3
Zganiacz, A.4
Xing, Z.5
-
24
-
-
8444222278
-
Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis
-
Wang, J., L. Thorson, R. W. Stokes, M. Santosuosso, K. Huygen, A. Zganiacz, M. Hitt, and Z. Xing. 2004. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173: 6357-6365.
-
(2004)
J. Immunol.
, vol.173
, pp. 6357-6365
-
-
Wang, J.1
Thorson, L.2
Stokes, R.W.3
Santosuosso, M.4
Huygen, K.5
Zganiacz, A.6
Hitt, M.7
Xing, Z.8
-
25
-
-
67649236987
-
Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis
-
Xing, Z., C. T. McFarland, J. M. Sallenave, A. Izzo, J. Wang, and D. N. McMurray. 2009. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One 4: e5856.
-
(2009)
PLoS One
, vol.4
-
-
Xing, Z.1
McFarland, C.T.2
Sallenave, J.M.3
Izzo, A.4
Wang, J.5
McMurray, D.N.6
-
26
-
-
84855444592
-
Rare serotype adenoviral vectors for HIV vaccine development
-
Michael, N. L. 2012. Rare serotype adenoviral vectors for HIV vaccine development. J. Clin. Invest. 122: 25-27.
-
(2012)
J. Clin. Invest.
, vol.122
, pp. 25-27
-
-
Michael, N.L.1
-
27
-
-
80053371681
-
Viruses: From pathogens to vaccine carriers
-
Small, J. C., and H. C. Ertl. 2011. Viruses: from pathogens to vaccine carriers. Curr. Opin. Virol. 1: 241-245.
-
(2011)
Curr. Opin. Virol.
, vol.1
, pp. 241-245
-
-
Small, J.C.1
Ertl, H.C.2
-
28
-
-
84873028543
-
Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors
-
Tan, W. G., H. T. Jin, E. E. West, P. Penaloza-MacMaster, A. Wieland, M. J. Zilliox, M. J. McElrath, D. H. Barouch, and R. Ahmed. 2013. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J. Virol. 87: 1359-1372.
-
(2013)
J. Virol.
, vol.87
, pp. 1359-1372
-
-
Tan, W.G.1
Jin, H.T.2
West, E.E.3
Penaloza-MacMaster, P.4
Wieland, A.5
Zilliox, M.J.6
McElrath, M.J.7
Barouch, D.H.8
Ahmed, R.9
-
29
-
-
84859514168
-
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults
-
Scriba, T. J., M. Tameris, E. Smit, L. van der Merwe, E. J. Hughes, B. Kadira, K. Mauff, S. Moyo, N. Brittain, A. Lawrie, et al. 2012. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am. J. Respir. Crit. Care Med. 185: 769-778.
-
(2012)
Am. J. Respir. Crit. Care Med.
, vol.185
, pp. 769-778
-
-
Scriba, T.J.1
Tameris, M.2
Smit, E.3
Van Der Merwe, L.4
Hughes, E.J.5
Kadira, B.6
Mauff, K.7
Moyo, S.8
Brittain, N.9
Lawrie, A.10
-
30
-
-
84875382846
-
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial
-
MVA85A 020 Trial Study Team
-
Tameris, M. D., M. Hatherill, B. S. Landry, T. J. Scriba, M. A. Snowden, S. Lockhart, J. E. Shea, J. B. McClain, G. D. Hussey, W. A. Hanekom, et al; MVA85A 020 Trial Study Team. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381: 1021-1028.
-
(2013)
Lancet
, vol.381
, pp. 1021-1028
-
-
Tameris, M.D.1
Hatherill, M.2
Landry, B.S.3
Scriba, T.J.4
Snowden, M.A.5
Lockhart, S.6
Shea, J.E.7
McClain, J.B.8
Hussey, G.D.9
Hanekom, W.A.10
-
31
-
-
77955517246
-
Novel adenovirus vector-based vaccines for HIV-1
-
Barouch, D. H. 2010. Novel adenovirus vector-based vaccines for HIV-1. Curr. Opin. HIV AIDS 5: 386-390.
-
(2010)
Curr. Opin. HIV AIDS
, vol.5
, pp. 386-390
-
-
Barouch, D.H.1
-
32
-
-
80053910021
-
Adenovirus 5-vectored P falciparum vaccine expressing CSP and AMA1. Part A: Safety and immunogenicity in seronegative adults
-
Sedegah, M., C. Tamminga, S. McGrath, B. House, H. Ganeshan, J. Lejano, E. Abot, G. J. Banania, R. Sayo, F. Farooq, et al. 2011. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 6: e24586.
-
(2011)
PLoS One
, vol.6
-
-
Sedegah, M.1
Tamminga, C.2
McGrath, S.3
House, B.4
Ganeshan, H.5
Lejano, J.6
Abot, E.7
Banania, G.J.8
Sayo, R.9
Farooq, F.10
-
33
-
-
80053894662
-
Adenovirus-5-vectored P falciparum vaccine expressing CSP and AMA1. Part B: Safety, immunogenicity and protective efficacy of the CSP component
-
Tamminga, C., M. Sedegah, D. Regis, I. Chuang, J. E. Epstein, M. Spring, J. Mendoza-Silveiras, S. McGrath, S. Maiolatesi, S. Reyes, et al. 2011. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One 6: e25868.
-
(2011)
PLoS One
, vol.6
-
-
Tamminga, C.1
Sedegah, M.2
Regis, D.3
Chuang, I.4
Epstein, J.E.5
Spring, M.6
Mendoza-Silveiras, J.7
McGrath, S.8
Maiolatesi, S.9
Reyes, S.10
-
34
-
-
80054003999
-
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVAB) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
-
García, F., J. C. Bernaldo de Quirós, C. E. Gómez, B. Perdiguero, J. L. Nájera, V. Jiménez, J. García-Arriaza, A. C. Guardo, I. Pérez, V. Díaz-Brito, et al. 2011. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVAB) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine 29: 8309-8316.
-
(2011)
Vaccine
, vol.29
, pp. 8309-8316
-
-
García, F.1
Bernaldo De Quirós, J.C.2
Gómez, C.E.3
Perdiguero, B.4
Nájera, J.L.5
Jiménez, V.6
García-Arriaza, J.7
Guardo, A.C.8
Pérez, I.9
Díaz-Brito, V.10
-
35
-
-
84860337949
-
DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults
-
Gorse, G. J., M. J. Newman, A. deCamp, C. M. Hay, S. C. De Rosa, E. Noonan, B. D. Livingston, J. D. Fuchs, S. A. Kalams, and F. L. Cassis-Ghavami; NIAID HIV Vaccine Trials Network. 2012. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin. Vaccine Immunol. 19: 649-658.
-
(2012)
Clin. Vaccine Immunol.
, vol.19
, pp. 649-658
-
-
Gorse, G.J.1
Newman, M.J.2
Decamp, A.3
Hay, C.M.4
De Rosa, S.C.5
Noonan, E.6
Livingston, B.D.7
Fuchs, J.D.8
Kalams, S.A.9
Cassis-Ghavami, F.L.10
-
36
-
-
84857399087
-
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
-
Sheehy, S. H., C. J. Duncan, S. C. Elias, S. Biswas, K. A. Collins, G. A. O'Hara, F. D. Halstead, K. J. Ewer, T. Mahungu, A. J. Spencer, et al. 2012. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7: e31208.
-
(2012)
PLoS One
, vol.7
-
-
Sheehy, S.H.1
Duncan, C.J.2
Elias, S.C.3
Biswas, S.4
Collins, K.A.5
O'Hara, G.A.6
Halstead, F.D.7
Ewer, K.J.8
Mahungu, T.9
Spencer, A.J.10
-
37
-
-
84862219175
-
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
-
Lillie, P. J., T. K. Berthoud, T. J. Powell, T. Lambe, C. Mullarkey, A. J. Spencer, M. Hamill, Y. Peng, M. E. Blais, C. J. Duncan, et al. 2012. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 55: 19-25.
-
(2012)
Clin. Infect. Dis.
, vol.55
, pp. 19-25
-
-
Lillie, P.J.1
Berthoud, T.K.2
Powell, T.J.3
Lambe, T.4
Mullarkey, C.5
Spencer, A.J.6
Hamill, M.7
Peng, Y.8
Blais, M.E.9
Duncan, C.J.10
-
38
-
-
84873634674
-
Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects
-
Greenberg, R. N., E. T. Overton, D. W. Haas, I. Frank, M. Goldman, A. von Krempelhuber, G. Virgin, N. Bädeker, J. Vollmar, and P. Chaplin. 2013. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J. Infect. Dis. 207: 749-758.
-
(2013)
J. Infect. Dis.
, vol.207
, pp. 749-758
-
-
Greenberg, R.N.1
Overton, E.T.2
Haas, D.W.3
Frank, I.4
Goldman, M.5
Von Krempelhuber, A.6
Virgin, G.7
Bädeker, N.8
Vollmar, J.9
Chaplin, P.10
-
39
-
-
77958498605
-
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa
-
Jaoko, W., E. Karita, K. Kayitenkore, G. Omosa-Manyonyi, S. Allen, S. Than, E. M. Adams, B. S. Graham, R. A. Koup, R. T. Bailer, et al. 2010. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 5: e12873.
-
(2010)
PLoS One
, vol.5
-
-
Jaoko, W.1
Karita, E.2
Kayitenkore, K.3
Omosa-Manyonyi, G.4
Allen, S.5
Than, S.6
Adams, E.M.7
Graham, B.S.8
Koup, R.A.9
Bailer, R.T.10
-
40
-
-
77749322238
-
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
-
VRC 009 Study Team; VRC 010 Study Team
-
Koup, R. A., M. Roederer, L. Lamoreaux, J. Fischer, L. Novik, M. C. Nason, B. D. Larkin, M. E. Enama, J. E. Ledgerwood, R. T. Bailer, et al; VRC 009 Study Team; VRC 010 Study Team. 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5: e9015.
-
(2010)
PLoS One
, vol.5
-
-
Koup, R.A.1
Roederer, M.2
Lamoreaux, L.3
Fischer, J.4
Novik, L.5
Nason, M.C.6
Larkin, B.D.7
Enama, M.E.8
Ledgerwood, J.E.9
Bailer, R.T.10
-
41
-
-
20944444088
-
Replicationdefective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates
-
Santra, S., M. S. Seaman, L. Xu, D. H. Barouch, C. I. Lord, M. A. Lifton, D. A. Gorgone, K. R. Beaudry, K. Svehla, B. Welcher, et al. 2005. Replicationdefective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J. Virol. 79: 6516-6522.
-
(2005)
J. Virol.
, vol.79
, pp. 6516-6522
-
-
Santra, S.1
Seaman, M.S.2
Xu, L.3
Barouch, D.H.4
Lord, C.I.5
Lifton, M.A.6
Gorgone, D.A.7
Beaudry, K.R.8
Svehla, K.9
Welcher, B.10
-
42
-
-
0030971268
-
HLA-A2.1-restricted education and cytolytic activity of CD8 (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice
-
Pascolo, S., N. Bervas, J. M. Ure, A. G. Smith, F. A. Lemonnier, and B. Pérarnau. 1997. HLA-A2.1-restricted education and cytolytic activity of CD8 (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 185: 2043-2051.
-
(1997)
J. Exp. Med.
, vol.185
, pp. 2043-2051
-
-
Pascolo, S.1
Bervas, N.2
Ure, J.M.3
Smith, A.G.4
Lemonnier, F.A.5
Pérarnau, B.6
-
43
-
-
0032587063
-
Single H2Kb, H2Db and double H2KbDb knockout mice: Peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses
-
Pérarnau, B., M. F. Saron, B. Reina San Martin, N. Bervas, H. Ong, M. J. Soloski, A. G. Smith, J. M. Ure, J. E. Gairin, and F. A. Lemonnier. 1999. Single H2Kb, H2Db and double H2KbDb knockout mice: peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur. J. Immunol. 29: 1243-1252.
-
(1999)
Eur. J. Immunol.
, vol.29
, pp. 1243-1252
-
-
Pérarnau, B.1
Saron, M.F.2
Reina San Martin, B.3
Bervas, N.4
Ong, H.5
Soloski, M.J.6
Smith, A.G.7
Ure, J.M.8
Gairin, J.E.9
Lemonnier, F.A.10
-
44
-
-
77953281795
-
New flow cytometric assays for monitoring cell-mediated cytotoxicity
-
Zaritskaya, L., M. R. Shurin, T. J. Sayers, and A. M. Malyguine. 2010. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev. Vaccines 9: 601-616.
-
(2010)
Expert Rev. Vaccines
, vol.9
, pp. 601-616
-
-
Zaritskaya, L.1
Shurin, M.R.2
Sayers, T.J.3
Malyguine, A.M.4
-
45
-
-
77950643077
-
Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis
-
Henao-Tamayo, M. I., D. J. Ordway, S. M. Irwin, S. Shang, C. Shanley, and I. M. Orme. 2010. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 17: 618-625.
-
(2010)
Clin. Vaccine Immunol.
, vol.17
, pp. 618-625
-
-
Henao-Tamayo, M.I.1
Ordway, D.J.2
Irwin, S.M.3
Shang, S.4
Shanley, C.5
Orme, I.M.6
-
46
-
-
22344433382
-
Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin
-
Grode, L., P. Seiler, S. Baumann, J. Hess, V. Brinkmann, A. Nasser Eddine, P. Mann, C. Goosmann, S. Bandermann, D. Smith, et al. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115: 2472-2479.
-
(2005)
J. Clin. Invest.
, vol.115
, pp. 2472-2479
-
-
Grode, L.1
Seiler, P.2
Baumann, S.3
Hess, J.4
Brinkmann, V.5
Nasser Eddine, A.6
Mann, P.7
Goosmann, C.8
Bandermann, S.9
Smith, D.10
-
47
-
-
0032574807
-
Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes
-
Hess, J., D. Miko, A. Catic, V. Lehmensiek, D. G. Russell, and S. H. Kaufmann. 1998. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. USA 95: 5299-5304.
-
(1998)
Proc. Natl. Acad. Sci. USA
, vol.95
, pp. 5299-5304
-
-
Hess, J.1
Miko, D.2
Catic, A.3
Lehmensiek, V.4
Russell, D.G.5
Kaufmann, S.H.6
-
48
-
-
80054745408
-
Recombinant BCG DureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses
-
Desel, C., A. Dorhoi, S. Bandermann, L. Grode, B. Eisele, and S. H. Kaufmann. 2011. Recombinant BCG DureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J. Infect. Dis. 204: 1573-1584.
-
(2011)
J. Infect. Dis.
, vol.204
, pp. 1573-1584
-
-
Desel, C.1
Dorhoi, A.2
Bandermann, S.3
Grode, L.4
Eisele, B.5
Kaufmann, S.H.6
-
49
-
-
84870546622
-
The recombinant tuberculosis vaccine rBCG DureC:Hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells
-
Farinacci, M., S. Weber, and S. H. Kaufmann. 2012. The recombinant tuberculosis vaccine rBCG DureC:hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells. Vaccine 30: 7608-7614.
-
(2012)
Vaccine
, vol.30
, pp. 7608-7614
-
-
Farinacci, M.1
Weber, S.2
Kaufmann, S.H.3
-
50
-
-
0034610299
-
Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model
-
Horwitz, M. A., G. Harth, B. J. Dillon, and S. Maslesa-Galic'. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97: 13853-13858.
-
(2000)
Proc. Natl. Acad. Sci. USA
, vol.97
, pp. 13853-13858
-
-
Horwitz, M.A.1
Harth, G.2
Dillon, B.J.3
Maslesa-Galic, S.4
-
51
-
-
0038751936
-
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
-
Pym, A. S., P. Brodin, L. Majlessi, R. Brosch, C. Demangel, A. Williams, K. E. Griffiths, G. Marchal, C. Leclerc, and S. T. Cole. 2003. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9: 533-539.
-
(2003)
Nat. Med.
, vol.9
, pp. 533-539
-
-
Pym, A.S.1
Brodin, P.2
Majlessi, L.3
Brosch, R.4
Demangel, C.5
Williams, A.6
Griffiths, K.E.7
Marchal, G.8
Leclerc, C.9
Cole, S.T.10
-
52
-
-
84872616132
-
Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis
-
Waeckerle-Men, Y., N. Bruffaerts, Y. Liang, F. Jurion, P. Sander, T. M. Kündig, K. Huygen, and P. Johansen. 2013. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine 31: 1057-1064.
-
(2013)
Vaccine
, vol.31
, pp. 1057-1064
-
-
Waeckerle-Men, Y.1
Bruffaerts, N.2
Liang, Y.3
Jurion, F.4
Sander, P.5
Kündig, T.M.6
Huygen, K.7
Johansen, P.8
-
53
-
-
0345269791
-
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virusinfected mice
-
Johnson, B. J., E. O. Costelloe, D. R. Fitzpatrick, J. B. Haanen, T. N. Schumacher, L. E. Brown, and A. Kelso. 2003. Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virusinfected mice. Proc. Natl. Acad. Sci. USA 100: 2657-2662.
-
(2003)
Proc. Natl. Acad. Sci. USA
, vol.100
, pp. 2657-2662
-
-
Johnson, B.J.1
Costelloe, E.O.2
Fitzpatrick, D.R.3
Haanen, J.B.4
Schumacher, T.N.5
Brown, L.E.6
Kelso, A.7
-
54
-
-
17844387159
-
Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection
-
Lawrence, C. W., R. M. Ream, and T. J. Braciale. 2005. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J. Immunol. 174: 5332-5340.
-
(2005)
J. Immunol.
, vol.174
, pp. 5332-5340
-
-
Lawrence, C.W.1
Ream, R.M.2
Braciale, T.J.3
-
55
-
-
80052309163
-
Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol
-
Bouillet, L. E., M. O. Dias, N. A. Dorigo, A. D. Moura, B. Russell, F. Nosten, L. Renia, E. M. Braga, R. T. Gazzinelli, M. M. Rodrigues, et al. 2011. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol. Infect. Immun. 79: 3642-3652.
-
(2011)
Infect. Immun.
, vol.79
, pp. 3642-3652
-
-
Bouillet, L.E.1
Dias, M.O.2
Dorigo, N.A.3
Moura, A.D.4
Russell, B.5
Nosten, F.6
Renia, L.7
Braga, E.M.8
Gazzinelli, R.T.9
Rodrigues, M.M.10
-
56
-
-
84856189784
-
Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol
-
Cayabyab, M. J., S. S. Kashino, and A. Campos-Neto. 2012. Robust immune response elicited by a novel and unique Mycobacterium tuberculosis protein using an optimized DNA/protein heterologous prime/boost protocol. Immunology 135: 216-225.
-
(2012)
Immunology
, vol.135
, pp. 216-225
-
-
Cayabyab, M.J.1
Kashino, S.S.2
Campos-Neto, A.3
-
57
-
-
73349094086
-
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
-
MOPH-TAVEG Investigators
-
Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 2209-2220
-
-
Rerks-Ngarm, S.1
Pitisuttithum, P.2
Nitayaphan, S.3
Kaewkungwal, J.4
Chiu, J.5
Paris, R.6
Premsri, N.7
Namwat, C.8
De Souza, M.9
Adams, E.10
-
58
-
-
34248329578
-
Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone
-
Stewart, V. A., S. M. McGrath, P. M. Dubois, M. G. Pau, P. Mettens, J. Shott, M. Cobb, J. R. Burge, D. Larson, L. A. Ware, et al. 2007. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75: 2283-2290.
-
(2007)
Infect. Immun.
, vol.75
, pp. 2283-2290
-
-
Stewart, V.A.1
McGrath, S.M.2
Dubois, P.M.3
Pau, M.G.4
Mettens, P.5
Shott, J.6
Cobb, M.7
Burge, J.R.8
Larson, D.9
Ware, L.A.10
-
59
-
-
84865436912
-
CD4+ T cell-dependent IFN-γ production by CD8+ effector T cells in Mycobacterium tuberculosis infection
-
Bold, T. D., and J. D. Ernst. 2012. CD4+ T cell-dependent IFN-γ production by CD8+ effector T cells in Mycobacterium tuberculosis infection. J. Immunol. 189: 2530-2536.
-
(2012)
J. Immunol.
, vol.189
, pp. 2530-2536
-
-
Bold, T.D.1
Ernst, J.D.2
|